Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended access momelotinib study for myelofibrosis
MOH_2018-06-14_002292Phase 2Active, not recruiting
- Sponsor
- GSK
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mivavotinib in myelofibrosis (MF), primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and 1 more, sponsored by GSK. Primary endpoint: Long-term safety of momelotinib. Started May 2018; status: active, not recruiting.
02
Drugs
mivavotinib
03
Conditions
myelofibrosis (MF)primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on MOH_2018-06-14_002292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-06-14_002292.